Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox Injection Clear all
Not listed Not applicable Interventional

Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

NCT06483217
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
Interventions
Patient-directed follow up
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone

NCT01186835
View directory record Official record
Conditions
Forehead/Glabellar Rhytid Complexes
Interventions
Combination Botulinum Toxin A and Hyaluronic Acid, Botulinum Toxin A
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Reduced-dose Botox for Urgency Incontinence Among Elder Females

NCT05512039
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
Interventions
Botox 50 Unit Injection, Botox 100 Unit Injection
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin for the Management of Chronic Orchialgia

NCT02058836
View directory record Official record
Conditions
Chronic Testicular Pain
Interventions
Botox Injection, Normal saline injection
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting No phase listed Observational

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

NCT07025044
View directory record Official record
Conditions
Overactive Bladder (OAB), Urge Incontinence
Interventions
onabotulinum toxin type a
Drug
Lead sponsor
Alexis Dieter
Other
Eligibility
55 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00311376
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal Saline (Placebo); botulinum toxin Type A (200U), Normal Saline (Placebo); botulinum toxin Type A (300U)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects

NCT00976443
View directory record Official record
Conditions
Obesity
Interventions
BTA, Placebo (normal saline)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT03571334
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

NCT00876447
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Middlebury, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 5:23 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines

NCT04249687
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Manhattan Beach, California • San Diego, California • Solana Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NCT05141006
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions
BOTOX, Placebo for BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 19, 2026, 5:23 AM EDT
Not listed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

NCT05485207
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

NCT02221648
View directory record Official record
Conditions
Lower Back Pain
Interventions
Placebo, AbobotulinumtoxinA Treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

NCT02965976
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Not yet recruiting Not applicable Interventional

False Vocal Fold vs EMG Guided Botox for Vocal Tremor

NCT07577310
View directory record Official record
Conditions
Vocal Tremor
Interventions
False Vocal Fold (FVF) botulinum toxin injections, Electromyography (EMG)-Guided Injection
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Incobotulinumtoxin A and Yoga-like Isometric Exercise in Adolescent Idiopathic Lumbar Scoliosis

NCT04922983
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis; Lumbar Region
Interventions
Botulinum toxin type A, Isometric Yoga-like exercise, Placebo
Drug · Behavioral
Lead sponsor
Manhattan Physical Medicine and Rehabilitation, LLP
Other
Eligibility
14 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

NCT03508921
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infections
Interventions
Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Chronic Migraine

NCT02074163
View directory record Official record
Conditions
Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24,, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction

NCT06161246
View directory record Official record
Conditions
Injection Site Discomfort
Interventions
Vibrating Beauty Bar
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated No phase listed Observational

PTNS vs Botox of Refractory OAB

NCT04451382
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
OnabotulinumtoxinA (BoNTA), Percutaneous tibial nerve stimulation (PTNS)
Biological · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 19, 2026, 5:23 AM EDT